trending Market Intelligence /marketintelligence/en/news-insights/trending/E2YSrwMuKrF70rrxZp0d-Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA faces lawsuit from Amgen

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA faces lawsuit from Amgen

Amgen Inc. filed a lawsuit against the U.S. Food and Drug Administration alleging that the regulator unlawfully denied pediatric exclusivity to one of its treatments.

Sensipar is meant to treat secondary hyperparathyroidism, which can lead to bone fractures and deformities. The drug is already approved for adults and was prescribed off label to the pediatric population, prompting the FDA to ask the company to investigate it in that population.

The U.S. FDA is required to grant six months of additional market exclusivity and patent protection to drugs for which pediatric studies have been requested.

However, the regulator denied exclusivity after the company failed to enroll the required number of patients in the study.

Amgen argued in the suit, filed with the U.S. District Court for the District of Columbia, that it was unable to find enough candidates due to lower patient population and that its study data be considered "fair" given the circumstances.

The plaintiff further said the studies are not required to demonstrate that the drugs are safe or effective in children to warrant pediatric exclusivity.

The company is seeking to have the regulator's decision overturned.

Sensipar generated $1.58 billion in global sales during 2016, and a pediatric exclusivity would help Amgen fend off generic competition.

A key patent covering Sensipar is due to expire in March 2018.

Amgen won a court ruling against Teva Pharmaceutical Industries Ltd. in 2011, blocking its attempt to launch a generic version of Sensipar. The company has filed separate lawsuits against 13 companies, including Mylan NV and Aurobindo Pharma Ltd., for infringing on a Sensipar patent.